Immunicon
Pioneering cell-based diagnostic solutions to empower physicians with timely and accurate cancer insights.
Pioneering cell-based diagnostic solutions to empower physicians with timely and accurate cancer insights.
Immunicon, a pioneer in cell-based diagnostic solutions, is revolutionizing the field of cancer diagnosis and treatment. The company's flagship product, CellTracks, enables the identification, counting, and characterization of tumor cells in blood samples, providing crucial insights to physicians and scientists at an early stage. In 2003, the company received a significant boost with a $24.75M Series F investment from a consortium of prominent investors including Canaan Partners, TL Ventures, Burrill & Company, Wheatley Partners, and Johnson & Johnson Development Corporation. This investment has positioned Immunicon for significant growth and market penetration. With an impressive track record dating back to 1983, Immunicon continues to expand its applications beyond cancer diagnostics, foreseeing opportunities in areas such as cardiovascular and infectious diseases. Teaming up with Veridex, LLC, (a Johnson & Johnson company), the company has demonstrated its commitment to delivering innovative solutions with real-world impact.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series F | $24.75M | 5 |
|
10 Jul 2003 |
| Series F | $29.00M | - | 01 Jun 2001 |
No recent news or press coverage available for Immunicon.
We care about your data, and we'd love to use cookies make your experience better.